Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
IPO Year:
Exchange: NYSE
Website: edwards.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $70.00 | Equal-Weight | Morgan Stanley |
| 9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies |
| 7/31/2024 | Neutral → Outperform | Daiwa Securities | |
| 7/29/2024 | Underperform → Peer Perform | Wolfe Research | |
| 7/25/2024 | $100.00 → $70.00 | Buy → Hold | TD Cowen |
| 7/25/2024 | $105.00 → $75.00 | Buy → Neutral | BofA Securities |
| 7/25/2024 | $102.00 → $70.00 | Outperform → Neutral | Robert W. Baird |
| 7/25/2024 | $105.00 → $72.00 | Overweight → Neutral | JP Morgan |
| 7/25/2024 | $110.00 → $82.00 | Buy → Hold | Truist |
| 5/30/2024 | $107.00 | Buy | Goldman |
Morgan Stanley resumed coverage of Edwards Lifesciences with a rating of Equal-Weight and set a new price target of $70.00
Jefferies downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $70.00 from $85.00 previously
Daiwa Securities upgraded Edwards Lifesciences from Neutral to Outperform
Wolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform
TD Cowen downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $70.00 from $100.00 previously
BofA Securities downgraded Edwards Lifesciences from Buy to Neutral and set a new price target of $75.00 from $105.00 previously
Robert W. Baird downgraded Edwards Lifesciences from Outperform to Neutral and set a new price target of $70.00 from $102.00 previously
JP Morgan downgraded Edwards Lifesciences from Overweight to Neutral and set a new price target of $72.00 from $105.00 previously
Truist downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $82.00 from $110.00 previously
Goldman initiated coverage of Edwards Lifesciences with a rating of Buy and set a new price target of $107.00
Edwards Lifesciences (NYSE:EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease. "The data at TCT on Edwards' innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians," said Bernard Zovighian, Edwards' CEO. "This new clinical evidence also advances Edwards' opportunities within both TAVR and TMTT to treat more patients with our advanced technologies and support long-term, sustainable growth ac
Edwards Lifesciences Corporation (NYSE:EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The data, presented during the late-breaking clinical trial sessions at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, included the full cohort of 400 patients. TRISCEND II trial one-year primary endpoint outcomes will be simultaneously published in
Edwards Lifesciences (NYSE:EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Founda
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enrollment in CLASP IITR trial for PASCAL tricuspid First implants in the JOURNEY pivotal trial with the Edwards J-Valve AR system Rei
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with
NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE:EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The data demonstrated that the 456 patients managed with Cordella in the study experienced a meaningful reduction in one-year HF hospitalization and all-cause mortality rate (36 events per 100 patients versus the 70 events per 100 patien
Company announces $1 billion share repurchase Edwards Lifesciences (NYSE:EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE:BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share repurchases. "Critical Care has made significant contributions to our company and has a long history of innovation. We are grateful to the team for their commitment to improving patient outcomes globally," said Bernard Zovighian, Edwards' CEO. "The sale of Critical Care reflects our sharpened focus as a structural heart
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves as compared to those receiving surgical aortic valve replacement (SAVR). "Women are an underrepresented group in the diagnosis and treatment of severe aortic stenosis and this landmark study provides important insights into their treatment options," said Hélène Eltchaninoff, M.D., head of
Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving an
Edwards Lifesciences (NYSE:EW) today announced investments that reflect the company's deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. JenaValve presented positive results of its U.S. pivotal trial for the treatment of symptomatic, severe AR in high-risk patients late last year. As the pioneer in valve innovation for more than 60 years, Edwar
10-Q - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
S-8 - Edwards Lifesciences Corp (0001099800) (Filer)
10-Q - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
11-K - Edwards Lifesciences Corp (0001099800) (Filer)
11-K - Edwards Lifesciences Corp (0001099800) (Filer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
3 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $70.
Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $100 to $90.
U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 0.5% on Thursday. Shares of Ford Motor Company (NYSE:F) fell sharply in today's pre-market trading following a second-quarter earnings miss. Ford reported second-quarter revenue of $47.8 billion, up 6% year-over-year. The revenue beat a Street consensus estimate of $44 billion according to data from Benzinga Pro. The company reported quarterly earnings per share of 47 cents, missing a Street consensus estimate of 68 cents. Ford Motor shares dipped 13% to $11.90 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Edwards Lifescience
EW: -24% | Edwards Lifesciences shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company acquired JenaValve and Endotronix. MXL: -27% | MaxLinear shares are trading lower after the company reported worse-than-expected Q2 financial results. POAI: 117% | Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $77.
Piper Sandler analyst Adam Maeder maintains Edwards Lifesciences (NYSE:EW) with a Neutral and lowers the price target from $88 to $73.
B of A Securities analyst Travis Steed downgrades Edwards Lifesciences (NYSE:EW) from Buy to Neutral and lowers the price target from $105 to $75.
JP Morgan analyst Robbie Marcus downgrades Edwards Lifesciences (NYSE:EW) from Overweight to Neutral and lowers the price target from $105 to $72.
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech space could once again drag the broader market after a few disappointing earnings reports from the likes of Franco-Italian chipmaker STMicroelectronics N.V. (NYSE:STM), which predominantly supplies to the automotive end market, and semiconductor test-equipment company Teradyne, Inc. (NASDAQ:TER). Traders may also stay glued to second-quarter GDP data to confirm the slowdown suggested by some recent data does not point to a hard landing. That said, bond yields are dipping as the market, factori
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enrollment in CLASP IITR trial for PASCAL tricuspid First implants in the JOURNEY pivotal trial with the Edwards J-Valve AR system Rei
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent patient outcomes; NCD process on track Critical Care sale expected to close late Q3 2024 Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMT
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives t
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT and Surgical; confident in TAVR guidance Critical Care spin-off on track; raising 2024 sales guidance "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategi
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying moderate AS patients Received early FDA approval for EVOQUE; ongoing European launch of EVOQUE Executed $400 million accelerated share repurchase in Q4; $867 million repurchased in 2023 Confident in 2024 gui
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing l
Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference. Highlights of today's conference include: Expecting early completion of enrollment in PROGRESS, studying moderate AS patients, in early 2024 Expecting data from EARLY TAVR, studying severe asymptomatic AS patients, at TCT 2024 Commercializing EVOQUE tricuspid valve in Europe; expecting U.S. approval mid-2024 Expecting CE Mark for SAPIEN M3 by the end of 2025 Reaffirming 2023 financial guidance Projecting 2024 global sales of $6.3 -
IRVINE, Calif., July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion; constant currency1 sales grew 12 percentAll product groups achieved double digit constant currency sales growth in Q2Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percentQ2 EPS of $0.50 (includes charge from previous IP agreement); adjusted1 EPS of $0.66Encouraging data from Edwards' Benchmark Registry at the EuroPCR medical congressNew 2023 constant c